Drug-Induced Graves Disease From CTLA-4 Receptor Suppression
Abstract
Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the literature, only nine cases of ICPi-induced Graves' hyperthyroidism and seven cases of induced Graves' orbitopathy have been described, associated with anti-PD-1 or anti-CTLA-4 treatment or their combination, with only one patient presenting both thyrotoxicosis and orbitopathy.
“To the best of our knowledge at the time of writing, only nine cases of ICPi-induced Graves’ hyperthyroidism and seven cases of induced Graves’ orbitopathy have been described in the literature, associated with anti-PD-1 or anti-CTLA-4 treatment or their combination (Table 3), with only one patient presenting with both thyrotoxicosis and orbitopathy [19,29,30,31,35,36,37,38,39,40,41,42,43,44].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [31]
Initially only induced Graves' orbitopathy without thyrotoxicosis were described in patients undergoing Ipilimumab treatment.
“In the literature, initially only induced Graves’ orbitopathy (GO) without thyrotoxicosis were described in patients undergoing Ipilimumab (anti-CTLA-4) treatment [29,30,31].”
From Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review) (2021) · cites this paper as [31]
HLA haplotypes associated with classic type 1 diabetes (DR3-DQ2 and DR4-DQ8) and with fulminant diabetes in Asian populations (DR4-DQ4 and DR9-DQ9) are over-represented among patients with immune checkpoint inhibitor-associated diabetes mellitus.
“Human leukocyte antigen (HLA) haplotypes linked with classic T1D (DR3-DQ2 and DR4-DQ8) and fulminant diabetes in the Asian population (DR4-DQ4 and DR9-DQ9) are over-represented among ICI-DM patients68”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
Cases of immune checkpoint inhibitor-associated diabetes mellitus in patients on CTLA-4 monotherapy are very rare.
“whereas reports of cases on CTLA-4 monotherapy are very rare”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
About 97% of reported cases of immune checkpoint inhibitor-associated diabetes mellitus have occurred in patients treated with anti-PD-1/PD-L1 agents or combination therapy.
“Approximately 97% of all reported ICI-DM cases have arisen with anti-PD-1/PD-L1 or combination treated patients”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [68]
Cites
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144 · see citing works
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
Yanagawa, T., Hidaka, Y., Guimarães, V. C., Soliman, M., & DeGroot, L. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.1.7829637 · Cited by 464 · see citing works
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343 · see citing works
Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity
Dittmar, M., & Kahaly, G. J. (2005) · Thyroid · doi:10.1089/thy.2005.15.239 · Cited by 70 · see citing works
Naik, V. M., Khadavi, N. M., Naik, M. N., Hwang, C. J., Goldberg, R. A., Tsirbas, A., Smith, T. J., & Douglas, R. S. (2008) · Thyroid · doi:10.1089/thy.2007.0403 · Cited by 37 · see citing works
Flagged first, then by citations
1 of the 6 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · see citing works
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 463 · see citing works
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441 · see citing works
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403 · see citing works
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018) · Retina · doi:10.1097/iae.0000000000002181 · Cited by 336 · see citing works
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 251 · see citing works
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Iyer, P. C., Cabanillas, M. E., Waguespack, S. G., Hu, M. I., Thosani, S., Lavis, V. R., Busaidy, N. L., Subudhi, S. K., Diab, A., & Dadu, R. (2018) · Thyroid · doi:10.1089/thy.2018.0116 · Cited by 238 · see citing works
Tarhini, A. A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 235 · see citing works
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224 · see citing works
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190 · see citing works
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172 · see citing works
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177 · see citing works
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139 · see citing works
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138 · see citing works
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J. S., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 137 · see citing works
Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A. (2015) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.1001858 · Cited by 128 · see citing works
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 127 · see citing works
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 118 · see citing works
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117 · see citing works
Thyroid disorders induced by checkpoint inhibitors
Ferrari, S. M., Fallahi, P., Galetta, F., Citi, E., Benvenga, S., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9463-2 · Cited by 112 · see citing works
Orbital Myositis: A Comprehensive Review and Reclassification
McNab, A. A. (2019) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001429 · Cited by 100 · see citing works
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93 · see citing works
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 92 · see citing works
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 82 · see citing works
Okada, N., Iwama, S., Okuji, T., Kobayashi, T., Yasuda, Y., Wada, E., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0736-7 · Cited by 78 · see citing works
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 75 · see citing works
Sagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., et al. (2019) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000001161 · Cited by 71 · see citing works
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70 · see citing works
Graves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Brancatella, A., Viola, N., Brogioni, S., Montanelli, L., Sardella, C., Vitti, P., Marcocci, C., Lupi, I., & Latrofa, F. (2019) · European Thyroid Journal · doi:10.1159/000501824 · Cited by 69 · see citing works
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Martens, A., Schauwvlieghe, P., Madoe, A., Casteels, I., & Aspeslagh, S. (2023) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-022-00321-2 · Cited by 68 · see citing works
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
Yu, C. W., Yau, M., Mezey, N., Joarder, I., & Micieli, J. A. (2020) · Eye and Brain · doi:10.2147/eb.s277760 · Cited by 62 · see citing works
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 60 · see citing works
Current and future immunotherapies for thyroid cancer
Antonelli, A., Ferrari, S. M., & Fallahi, P. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417845 · Cited by 58 · see citing works
A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis
Yu, C. H., CHOPRA, I. J., & Ha, E. L. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0092 · Cited by 49 · see citing works
Anticancer Drug-induced Thyroid Dysfunction
Bhattacharya, S., Goyal, A., Kaur, P., Medanta, T. M., Singh, R. K., & Kalra, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.32 · Cited by 49 · see citing works
Immunotherapy-induced endocrinopathies: assessment, management and monitoring
Nogueira, E. F., Newsom‐Davis, T., & Morganstein, D. L. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819896182 · Cited by 48 · see citing works
Ocular Inflammation Induced by Immune Checkpoint Inhibitors
Chaudot, F., Sève, P., Rousseau, A., Maria, A. T. J., Fournié, P., Lozac’h, P., Keraen, J., Servant, M., Muller, R., Gramont, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174993 · Cited by 46 · see citing works
Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma
Modjtahedi, B. S., Maïbach, H. I., & Park, S. (2013) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2013.781618 · Cited by 46 · see citing works
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 45 · see citing works
Li, Z., Cestari, D. M., & Fortin, É. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000529 · Cited by 43 · see citing works
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 43 · see citing works
Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment
Campredon, P., Imbert, P., Mouly, C., Grunenwald, S., Mazières, J., & Caron, P. J. (2018) · European Thyroid Journal · doi:10.1159/000485742 · Cited by 42 · see citing works
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
Sabbagh, R. E., Azar, N. S., Eid, A. A., & Azar, S. T. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s261433 · Cited by 43 · see citing works
Zhou, Y., Wang, Y., Xia, R.-L., Liu, J., & Ma, X. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.04.19 · Cited by 42 · see citing works
Inflammatory Orbitopathy Associated With Ipilimumab
Sheldon, C. A., Kharlip, J., & Tamhankar, M. A. (2015) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000509 · Cited by 38 · see citing works
Carl, D. J., Grüllich, C., Hering, S., & Schabet, M. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1283-9 · Cited by 36 · see citing works
New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V. E. A., & Modorati, G. M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.10.010 · Cited by 35 · see citing works
Kheir, W. J., Sniegowski, M. C., El-Sawy, T., Li, A. L., & Esmaeli, B. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.02.004 · Cited by 34 · see citing works
Vouk, K., Benter, U., Amonkar, M. M., Marocco, A., Stapelkamp, C., Pfersch, S., & Benjamin, L. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184155 · Cited by 33 · see citing works
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
Henderson, A. D., & Thomas, D. A. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000081 · Cited by 34 · see citing works
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33 · see citing works
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
Hager, T., & Seitz, B. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s54606 · Cited by 33 · see citing works
Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction
Wright, J. J., & Johnson, D. B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac689 · Cited by 31 · see citing works
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29 · see citing works
Immune checkpoints: new insights into the pathogenesis of thyroid eye disease
Shu, X., Shao, Y., Chen, Y., Zeng, C., Huang, X., & Wei, R.-L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392956 · Cited by 29 · see citing works
Ocular side effects of checkpoint inhibitors
Alba‐Linero, C., & Alba, E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.01.001 · Cited by 29 · see citing works
Percik, R., Criseno, S., Adam, S., Young, K., & Morganstein, D. L. (2023) · Endocrine Connections · doi:10.1530/ec-22-0513 · Cited by 28 · see citing works
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27 · see citing works
Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review
Wu, K. Y., Yakobi, Y., Gueorguieva, D. D., & Mazerolle, É. (2024) · Biomedicines · doi:10.3390/biomedicines12112547 · Cited by 26 · see citing works
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26 · see citing works
Endocrine toxicity of cancer immunotherapy: clinical challenges
Anderson, B., & Morganstein, D. L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0489 · Cited by 26 · see citing works
Pawłowski, P., Wawrusiewicz-Kurylonek, N., Eckstein, A. K., Reszeć, J., Łuczyński, W., Johnson, K. T. M., Kretowski, A. J., Bakunowicz‐Łazarczyk, A., Górska, M., Szamatowicz, J., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/340934 · Cited by 26 · see citing works
Immune checkpoint inhibitors and endocrine side effects, a narrative review
Agrawal, L., Bacal, A., Jain, S., Singh, V., Emanuele, N. V., Emanuele, M. A., & Meah, F. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1709344 · Cited by 26 · see citing works
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy
Park, E. S., Rabinowits, G., Hamnvik, O. R., & Dagi, L. R. (2018) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2018.01.006 · Cited by 22 · see citing works
Borodic, G. E., & Hinkle, D. M. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000033 · Cited by 20 · see citing works
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.05.005 · Cited by 20 · see citing works
Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma
Alnabulsi, R., Hussain, A., & DeAngelis, D. (2018) · Orbit · doi:10.1080/01676830.2017.1423349 · Cited by 19 · see citing works
Implications of FoxP3-positive and -negative CD4+ CD25+ T cells in Graves’ ophthalmopathy
Matsuzawa, K., Izawa, S., Okura, T., Fujii, S., Matsumoto, K., Shoji, K., Nakamura, R., Sumi, K., Fujioka, Y., Yoshida, A., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0108 · Cited by 19 · see citing works
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18 · see citing works
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Corsello, S. M., Salvatori, R., Barnabei, A., Vecchis, L. D., Marchetti, P., & Torino, F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2213-y · Cited by 17 · see citing works
Gridelli, C. (2016) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/3/1/00143 · Cited by 15 · see citing works
Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology
Davis, M. E., & Francis, J. H. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.003 · Cited by 15 · see citing works
Eikenberry, J. L., Harris, A., Torabi, R., Lang, M., Denney, D., Vercellin, A. C. V., & Siesky, B. A. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120930688 · Cited by 15 · see citing works
The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors
Mai, K., Faßnacht, M., Führer‐Sakel, D., Honegger, J. B., Weber, M. M., & Kroiß, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0143 · Cited by 15 · see citing works
Sohrab, M. A., Desai, R. U., Chambers, C. B., & Lissner, G. S. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e3182895795 · Cited by 14 · see citing works
Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets
Cieplińska, K., Niedziela, E., & Kowalska, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010072 · Cited by 13 · see citing works
Metastatic melanoma: Pathologic characterization, current treatment, and complications of therapy
Wick, M. R., & Gru, A. A. (2016) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.04.005 · Cited by 13 · see citing works
Ipilimumab-related orbitopathy: a case report
Jebaraj, A. P., Etheridge, T. J., Winegar, B. A., & Marx, D. P. (2022) · Orbit · doi:10.1080/01676830.2022.2074049 · Cited by 11 · see citing works
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047_g · Cited by 11 · see citing works
Molecularly targeted agents in oculoplastic surgery
Allen, R. C. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000403 · Cited by 11 · see citing works
Nardin, C., Borot, S., Beaudoin, M. A., Cattin, F., Puzenat, E., Gauthier, A.-S., Schillo, F., Borg, C., & Aubin, F. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0659-9 · Cited by 10 · see citing works
Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors
Mukharesh, L., & Chwalisz, B. K. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1890796 · Cited by 10 · see citing works
Douglas, V. P., Douglas, K. A. A., & Cestari, D. M. (2019) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000608 · Cited by 9 · see citing works
Chau, C. Y. C., Shih, K. C., Chow, L. L. W., & Lee, V. H.-F. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00317-y · Cited by 9 · see citing works
Effets indésirables oculaires des traitements systémiques : une mise à jour
Rousseau, A., & Labétoulle, M. (2015) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2015.05.004 · Cited by 7 · see citing works
Borodic, G. E., & Hinkle, D. M. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e31828957c3 · Cited by 7 · see citing works
Madala, S., Parikh, A. O., Hong, K., & Burnstine, M. A. (2025) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1574643 · Cited by 5 · see citing works
Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit
Park, B. J., Warning, A. W., & Akella, S. S. (2024) · Orbit · doi:10.1080/01676830.2024.2351519 · Cited by 5 · see citing works
Pathogenesis of Thyroid Eye Disease
Spadaro, J. Z., & Kohli, A. A. (2023) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000464 · Cited by 5 · see citing works
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
Hammerstad, S. S., Lee, H. J., Tomer, Y., & Stefan–Lifshitz, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02608-2 · Cited by 4 · see citing works
Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A.-I., & Badiu, C. (2025) · Cancers · doi:10.3390/cancers17071198 · Cited by 4 · see citing works
Lenalidomide-Associated Thyroid-Related Eyelid Retraction
Slean, G. R., & Silkiss, R. Z. (2017) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001012 · Cited by 4 · see citing works
R-CHOP-Associated Graves’ Hyperthyroidism
Mora, N., Vu, K., Hoang, T. D., Mai, V. Q., & Shakir, M. K. M. (2019) · Case Reports in Oncology · doi:10.1159/000501714 · Cited by 4 · see citing works
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
Torino, F., Barnabei, A., Baldelli, R., & Appetecchi, M. (2012) · InTech eBooks · doi:10.5772/50375 · Cited by 4 · see citing works
Pan, M., Zhou, X., & Wu, Y. F. (2025) · Diagnostics · doi:10.3390/diagnostics15212764 · Cited by 3 · see citing works
Targeted Therapy and Their Ocular Complications
Jusufbegovic, D., Triozzi, P. L., & Singh, A. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40489-4_13 · Cited by 3 · see citing works
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.12.001 · Cited by 4 · see citing works
Iatrogenic affectation of ocular motility by immune checkpoint inhibitors
Jiménez-Ortiz, H. F., Rodríguez, B. M., Monjas, R. L., Yáñez, R. S., Santos, I. S., & Fernández, N. T. (2023) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2023.11.011 · Cited by 2 · see citing works
Souri, Z., & Pakdel, F. (2024) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v19i3.15047 · Cited by 2 · see citing works
- Authors
- Borodic, G., Hinkle, D. M., & Cia, Y.
- Affiliations
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- Corresponding author
- Borodic, Gary
- ORCID
- Hinkle, David M.
- Venue
- Ophthalmic Plastic & Reconstructive Surgery
- Published
- 2011-07
- Volume
- 27
- Issue
- 4
- Pages
- e87-e88
- ISSN
- 0740-9303 (ISSN-L)
- OpenAlex
- W1988822265
- Cited by
- 120
- References
- 6
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 13 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 4 · 2013: 10 · 2012: 2
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Ophthalmic Plastic and Reconstructive Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
- Keywords
- ipilimumab, CTLA-4 blockade, Graves' ophthalmopathy, T cell suppression, metastatic melanoma, CTLA-4 gene polymorphism, autoimmune thyroid disease
- MeSH terms
- Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Diplopia, Exophthalmos, Female, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Melanoma, Middle Aged, Neoplasms, Unknown Primary, Oculomotor Muscles, Antigens, CD, Graves Ophthalmopathy, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
